NEW YORK--(Business Wire)--Reportlinker.com announces that a new market research report
related to the Pharmaceutical industry is available in its catalogue.
***************************
Bayer Schering Pharma AG: Company Profile
To order that report:
www.reportlinker.com/p073695/Bayer-Schering-Pharma-AG-Company
-Profile.html
For more information, contact Nicolas by email
nbo@reportlinker.com, by phone +33 4 37 65 17 03.
***************************
This analysis examines the historical and forecast performance for
Bayer Schering in the ethical pharma sector. The profile encompasses
global company strategy, portfolio and pipeline analysis and
assessment of financial performance, with 1-6 year sales forecasts for
key drugs. An interactive forecasting and analysis tool provides
continually updated quantitative and qualitative information.
Benchmark Bayer Schering's performance against key rivals in the
ethical pharmaceutical sector Assess the commercial advantages that
underscore the 2006 merger of Bayer and Schering AG Analyze the
therapeutic focus of the merged company, including its core focus on
the women's health and oncology segments
CHAPTER 1 EXECUTIVE SUMMARY 2
Key findings 2
Historical and forecast ethical sales performance 3
Therapeutic strategy 5
Launch and expiry outlook 8
Externalization, geographic and molecule type strategies 10
Externalization strategy 11
Geographic strategy 12
Molecule type strategy 12
Growth by company 14
SWOT analysis 16
Strengths 16
Weaknesses 17
Opportunities 17
Threats 18
CHAPTER 2 CORPORATE HISTORY 21
Key findings 21
Background 22
Key corporate developments 22
M&A history 23
Acquisition of Roche Consumer Care 23
Divestment of LANXESS 23
Acquisition of Schering AG 24
M&A in the Mid Pharma sector 24
Schering the target of acquisition 24
Divestments promote focus on ethical pharma 25
Divestment of H.C. Starck and Wolff Walstrode 25
Divestment of Diagnostics Division 25
M&A strategy 25
Current corporate structure 26
Bayer HealthCare 26
Bayer MaterialScience 27
Bayer CropScience 27
Current management team 28
CHAPTER 3 HISTORICAL PERFORMANCE 29
Key findings 29
Introduction 30
Revenue and growth rate analysis, 2001-06 30
Revenue and growth rate vs. peer set 33
Product analysis, 2001-06 35
Growth drivers 35
Yasmin 35
Betaferon 36
Kogenate 36
Levitra 36
Avelox 36
Mirena 36
Growth resistors 37
Cipro 37
Adalat 37
Aspirin 37
Operating revenue and cost analysis, 2001-06 38
Operating revenue/cost analysis 40
CHAPTER 4 FORECAST PERFORMANCE 42
Key findings 42
Introduction 43
Revenue and growth rate, 2006-12 43
Product analysis, 2006-12 44
Growth drivers 49
Nexavar 49
Yaz 50
Rivaroxaban 50
Kogenate 50
Mirena 50
Growth resistors 51
Adalat 51
Cipro 51
Trasylol 51
Meliane 51
Therapy area analysis, 2006-12 53
Urology and sexual health 55
Oncology 56
Cardiovascular and hematology 56
Respiratory and infectious disease 56
Therapy area focus 57
Launches and expiries analysis, 2006-12 60
Launch portfolio 60
Core portfolio 63
Expiry portfolio 66
Launch/core/expiry configuration 68
Externalization analysis, 2006-12 71
Geographic analysis, 2006-12 76
Molecule type analysis, 2006-12 80
CHAPTER 5 KEY PRODUCTS AND COMPETITORS 85
Key findings 85
Overview 86
Urology and sexual health 87
Yasmin 87
Overview 87
Sales forecast 88
Competitive landscape 88
Yaz 91
Overview 91
Sales forecast 92
Newsflow 92
Competitive landscape 93
Mirena 95
Overview 95
Sales forecast 96
Newsflow 96
Competitive landscape 97
Levitra 99
Overview 99
Sales forecast 100
Newsflow 100
Competitive landscape 101
Cardiovascular and hematology 103
Kogenate 103
Overview 103
Sales forecast 104
Newsflow 104
Competitive landscape 105
Rivaroxaban (Xarelto) 107
Overview 107
Sales forecast 108
Newsflow 108
Competitive landscape 109
Oncology 111
Nexavar 111
Overview 111
Sales forecast 112
Newsflow 113
Competitive landscape 114
Campath 116
Overview 116
Sales forecast 117
Newsflow 117
Competitive landscape 118
CNS 119
Betaferon/Betaseron 119
Overview 119
Sales forecast 120
Newsflow 120
Competitive landscape 121
Infectious disease 124
Avelox 124
Overview 124
Sales forecast 125
Competitive landscape 125
Cipro 127
Overview 127
Sales forecast 128
Competitive landscape 128
R&D pipeline 131
Lifecycle management pipeline 132
CHAPTER 6 APPENDIX 133
IMS vs. company-reported data reconciliation 133
References 136
Abbreviations 136
Exchange rates 137
List of Tables
Table 1: Bayer HealthCare Executive Board 28
Table 2: Peer set overview 33
Table 3: Operating revenue/cost analysis ($m), 2001-06 38
Table 4: Operating cost ratio analysis (% of total revenues),
2001-06 40
Table 5: Product portfolio overview, sales ($m), 2006-12 44
Table 6: Therapy area overview, sales ($m), 2006-12 53
Table 7: Launch portfolio overview, sales ($m), 2006-12 60
Table 8: Core portfolio overview, sales ($m), 2006-12 63
Table 9: Expiry portfolio overview, sales ($m), 2006-12 66
Table 10: Externally developed portfolio ($m), 2006-12 71
Table 11: Molecule type overview, sales ($m), 2006-12 80
Table 12: Key products overview 86
Table 13: Yasmin: overview 87
Table 14: Yasmin: sales forecast ($m), 2006-12 88
Table 15: Yaz: overview 91
Table 16: Yaz: sales forecast ($m), 2006-12 92
Table 17: Yaz: newsflow 92
Table 18: Mirena: overview 95
Table 19: Mirena: sales forecast ($m), 2006-12 96
Table 20: Yaz: newsflow 96
Table 21: Levitra: overview 99
Table 22: Levitra: sales forecast ($m), 2006-12 100
Table 23: Levitra: newsflow 100
Table 24: Kogenate: overview 103
Table 25: Kogenate: sales forecast ($m), 2006-12 104
Table 26: Rivaroxaban: newsflow 104
Table 27: Rivaroxaban: overview 107
Table 28: Rivaroxaban: sales forecast ($m), 2006-12 108
Table 29: Rivaroxaban: newsflow 108
Table 30: Nexavar: overview 111
Table 31: Nexavar: sales forecast ($m), 2006-12 112
Table 32: Nexavar: newsflow 113
Table 33: Campath: overview 116
Table 34: Campath: sales forecast ($m), 2006-12 117
Table 35: Campath: newsflow 117
Table 36: Betaferon/Betaseron: overview 119
Table 37: Betaferon/Betaseron: sales forecast ($m), 2006-12 120
Table 38: Betaferon/Betaseron: newsflow 120
Table 39: Avelox: overview 124
Table 40: Avelox: sales forecast ($m), 2006-12 125
Table 41: Cipro: overview 127
Table 42: Cipro: sales forecast ($m), 2006-12 128
Table 43: Bayer Schering's R&D pipeline (Phase I-registration) 131
Table 44: Bayer Schering's lifecycle management pipeline (Phase
I-registration) 132
Table 45: Exchange rates, 2006 137
List of Figures
Figure 1: Historical and forecast ethical sales performance (%
CAGR), Bayer Schering and Big Pharma peer set 4
Figure 2: Therapeutic focus vs. Big Pharma peer set (%), 2006 7
Figure 3: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), Bayer Schering 8
Figure 4: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), peer set 9
Figure 5: Molecule type, externalization and geographic market
dependency (%) vs. peer set, 2006 10
Figure 6: Molecule type, externalization and geographic market
dependency (%) vs. peer set, 2012 11
Figure 7: Growth drivers by company, sales ($m), 2006-12 14
Figure 8: SWOT analysis of Bayer Schering 16
Figure 9: M&A/divestment history 23
Figure 10: Current corporate structure 26
Figure 11: Bayer Schering revenue & growth rate (ethical sales)
($m), 2001-06 30
Figure 12: Bayer and Schering Revenue & growth rate (ethical
sales) ($m), 2001-06 31
Figure 13: Growth drivers by company (ethical sales) ($m), 2001-06
32
Figure 14: Ethical revenue ($m) and growth rate (%) vs. peer set,
2001-06 34
Figure 15: Growth drivers/resistor products of historical revenue
performance ($m), 2001-06 35
Figure 16: Operating revenue/cost analysis ($m), 2001-06 39
Figure 17: Operating cost ratio analysis (% of total revenues),
2001-06 41
Figure 18: Ethical revenue ($m) and growth rate (%), 2006-12 43
Figure 19: Top five products by sales ($m), 2006 46
Figure 20: Top five products by sales ($m), 2012 47
Figure 21: Growth drivers and resistors by product, 2006-12 49
Figure 22: Key strategic products, sales ($m), 2006-12 52
Figure 23: Ethical sales by therapy area ($m), 2006-12 54
Figure 24: Growth drivers and resistors by therapy area ($m),
2006-12 55
Figure 25: Ethical sales by therapy area (%), 2006-12 57
Figure 26: Therapy area focus compared with peer set (% total
ethical sales), 2006 58
Figure 27: Therapy area focus compared with peer set (% total
ethical sales), 2012 59
Figure 28: Launch schedule, sales ($m), 2006-12 61
Figure 29: Core products sales growth ($m), 2006-12 64
Figure 30: Expiry schedule (top 10), sales ($m), 2006-12 67
Figure 31: Launch, core and expiry, sales ($m), 2006-12 68
Figure 32: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), Bayer Schering 69
Figure 33: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), peer set 70
Figure 34: Externalization dependency, sales ($m), 2006-12 72
Figure 35: Growth drivers and resistors, externally vs. internally
discovered products, sales ($m), 2006-12 73
Figure 36: Externalization dependency vs. peer set, % total sales,
2006 74
Figure 37: Externalization dependency vs. peer set, % total sales,
2012 75
Figure 38: Geographical sales breakdown ($m), 2006-12 76
Figure 39: Growth drivers and resistors by geographical region,
sales ($m), 2006-12 77
Figure 40: US dependency vs. peer set, % total sales, 2006 78
Figure 41: US dependency vs. peer set, % total sales, 2012 79
Figure 42: Growth drivers and resistors by molecule type, sales
($m), 2006-12 81
Figure 43: Molecule type sales breakdown ($m), 2006-12 82
Figure 44: Biologics dependency vs. peer set, % total sales, 2006
83
Figure 45: Biologics dependency vs. peer set, % total sales, 2012
84
Figure 46: IMS vs. company-reported ethical sales discrepancy
($m), 2006 134
Figure 47: IMS vs. company-reported ethical sales forecast growth
rates (%), 2006-12 135
To order that report:
www.reportlinker.com/p073695/Bayer-Schering-Pharma-AG-PharmaVitae
-Profile.html
For more information, contact Nicolas by email
nbo@reportlinker.com, or by phone +33 4 37 65 17 03.
More market research reports?
Go to http://www.reportlinker.com
(Due to their length, the URLs may need to be copied/pasted into
your Internet browser's address field. Remove the extra space if one
exists.)
Reportlinker.com
Nicolas, +33 4 37 65 17 03
nbo@reportlinker.com
Copyright Business Wire 2008
